Physician profile
Jonathan Brisson
NPI 1265712160
$1,184.01
in general payments reported to CMS, 2019-2025
19 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $31.65 · 2021: $24.70 · 2022: $85.26 · 2023: $127 · 2024: $76.69 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $154.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $137.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $125.24 | 2025 | Rexulti |
| Pfizer INC. | $110.88 | 2019-2025 | |
| Novo Nordisk INC | $102.69 | 2023-2025 | Wegovy, Rybelsus |
| Amgen INC. | $98.67 | 2019-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $86.98 | 2019-2025 | Capvaxive |
| Exact Sciences Corporation | $85.92 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $44.41 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $42.02 | 2019-2022 | |
| Abbvie INC. | $40.58 | 2021-2023 | Vraylar |
| Lilly USA, LLC | $33.52 | 2022-2023 | Mounjaro |
| Boston Scientific Corporation | $29.56 | 2023 | Watchman Flx |
| Radius Health, INC. | $20.33 | 2023 | Tymlos |
| Aimmune Therapeutics, INC. | $15.38 | 2025 | Zenpep |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $14.86 | 2022 | |
| Allergan, INC. | $14.61 | 2019 | |
| Amarin Pharma, INC. | $14.20 | 2019 | |
| Sanofi Pasteur INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Brisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.